Search
GI Cancer
ALLIANCE A212102 **AT MBMC ONLY** **White female participants under (<) age 60 without a cancer diagnosis will temporarily be suspended on 12/1/22 3:30 cst**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
ECOG-ACRIN EA2197 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
OPTIMAL PERIOPERATIVE THERAPY FOR INCIDENTAL GALLBLADDER CANCER (OPT-IN): A RANDOMIZED PHASE II/III TRIAL
ECOG-ACRIN EA2201 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
s2104 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
EA2192
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
NCI 10323
Cancer Moonshot Biobank Research Protocol
NSABP C-14 / CORRECT-MRD II
Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
